<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160263</url>
  </required_header>
  <id_info>
    <org_study_id>P080402</org_study_id>
    <secondary_id>P080402</secondary_id>
    <secondary_id>AOM 07225</secondary_id>
    <nct_id>NCT01160263</nct_id>
  </id_info>
  <brief_title>Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls</brief_title>
  <acronym>DOSERAL</acronym>
  <official_title>Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Française contre les Myopathies (AFM), Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARS (Association pour la Recherche sur la Sclérose Latérale Amyotrophique)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agence Générale des Equipements et Produits de Santé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the transporters of serotonin and dopamine in ALS
      patients in relation with the clinical phenotype, i.e., patients without stiffness, patients
      with pyramidal stiffness, patients with mixed (pyramidal and extra pyramidal) stiffness.

      For such a goal the investigators will use SPECT to compare the binding of two specific
      tracers in ALS patients and in matched healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design This study is a prospective cross-sectional controlled multicentric clinical
      study in 60 ALS patients and 20 controls.

      Three cohorts of 20 ALS patients(patients without stiffness, patients with pyramidal
      stiffness, patients with mixed pyramidal and extra pyramidal stiffness) and 20 healthy
      controls will be included in this study

      Study centres 40 ALS patients and 13 controls will be included in the Paris ALS center, 20
      ALS patients and 7 controls will be included in the Tours ALS center.

      MRI will be performed at the Neuroradiology department of salpetriere hospital (Paris) and
      Bretonneau hospital (Tours) SPECT will be done in the nuclear medicine center of each
      hospital (Paris- Tours).

      Study duration Per patient or control, the study will be lasted one month. The total study
      duration will be two years
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine transporter binding potential</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotonin transporter binding potential</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationships between transporter binding potential and the clinical scores</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>patients without stiffness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with pyramidal stiffness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with mixed stiffness</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM</intervention_name>
    <description>123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.
123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter.</description>
    <arm_group_label>patients without stiffness</arm_group_label>
    <arm_group_label>patients with pyramidal stiffness</arm_group_label>
    <arm_group_label>patients with mixed stiffness</arm_group_label>
    <other_name>PECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients (men or women)

               -  between 39 (exclusive) and 66 (inclusive) years old

               -  with a sporadic ALS, defined, probable or laboratory possible

               -  with a disease duration between 3 months (inclusive) and 5 years (exclusive)

               -  treated with rilutek at 100 mg/ day since at least 1 month

          2. Patients will be assigned in three groups in relation with the clinical phenotypes:

               -  20 patients without stiffness

               -  20 patients with pyramidal stiffness (spasticity patients).

               -  20 patients with mixed stiffness (both spasticity and rigidity).

          3. Patients have to be capable of thoroughly understanding the information given; have
             signed the informed consent form (signature of spouse or family relative or acceptable
             third party is acceptable if the patient is physically unable to sign).

          4. To have social insurance

        Exclusion Criteria:

          1. Patients with a FRONTO temporal dementia (according to NEARY' criteria)

          2. Patients with any concomitant life-threatening disease or any disease or impairment
             likely to interfere with functional assessment;

          3. Patients with any major evolving psychiatric disorder or major anxiety disorder
             according to DSM-IV criteria (APA, 1996)

          4. Patients receiving treatments which could interfere with the serotonin or dopamine
             metabolism

          5. Patients with contraindications for the dat-scan and /or ADAM scan

          6. Patients with contraindications for the MRI scan.

          7. Patients with previous vascular, traumatic or tumoral cerebral lesions making
             impossible the quantification of the tracer

          8. Patients with a cancer within the past 5

          9. Patients child bearing, breast feeding or in the second part of their cycle without
             any efficient contraceptive device or treatment

         10. Patients liable not to be co-operative or comply with the trial requirements (as
             assessed by the investigator), or unable to be reached in the event of an emergency;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>39 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucette Lacomblez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié-Salpêtrière Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bretonneau Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>May 12, 2015</last_update_submitted>
  <last_update_submitted_qc>May 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>serotonin</keyword>
  <keyword>dopamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

